Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Khiron Life Sciences Corp KHRNF


Primary Symbol: V.KHRN.H Alternate Symbol(s):  V.KHRN.WT.H | KHRWF

Khiron Life Sciences Corp. is a Canada-based medical cannabis company with core operations in Latin America. The Company has its wholly owned medical health clinics and telemedicine platforms. The Company has two product lines: Medical Cannabis Products and Health Services. It sells branded medical cannabis products to patients with medical conditions. Under the Medical Cannabis Products line, the Company is focused on product sales in Latin America. The Company operates its own network of health centers (operating under the Zerenia brand) and Zerenia satellite clinics offering a suite of health, medical and surgical services, in alignment with both insurance company partners and private practice. Its subsidiaries include Khiron Life Sciences Corp. (Canada), Khiron Colombia S.A.S., Zerenia S.A.S., NettaGrowth International Inc., and others.


TSXV:KHRN.H - Post by User

Comment by Benedictuson Jun 05, 2021 11:26am
230 Views
Post# 33335947

RE:RE:I'm hoping this dog will run soon!

RE:RE:I'm hoping this dog will run soon! The race is on between the cash burn and revenue build and unfortunately the cash burn is ahead by a country mile. The execution is definitely coming together with script issuance growth, good customer retention, insurance coverage and adding more sales in Germany and the UK, BUT the company does not have 2 full quarters of cash left and they cannot close the gap. They need funds and will have to do a raise. I'm waiting to see if the terms are better than last time. 
<< Previous
Bullboard Posts
Next >>